Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug enters early human trials for tough cancers

NCT ID NCT06178614

First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 27 times

Summary

This early-stage study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. About 200 adults with certain types of kidney, ovarian, uterine, colorectal, or lung cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Leon Berard

    RECRUITING

    Lyon, 69008, France

  • Hosp Univ Vall D Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hosp. Univ. 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Start Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

Conditions

Explore the condition pages connected to this study.